
    
      Clear cell mRCC patients who initiated sunitinib as first-line treatment between 2010 and
      2018 were identified from the IMDC database. Patients were classified as favorable,
      intermediate, or poor prognostic risk group according to IMDC criteria. Overall survival,
      time to treatment discontinuation, and physician-assessed tumor response were evaluated.
    
  